Q BioMed Income Statement

Financials in millions USD. Fiscal year is December - November.

Millions USD. Fiscal year is Dec - Nov.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Feb '23 Feb 28, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021	Nov '20 Nov 30, 2020	Nov '19 Nov 30, 2019	Nov '18 Nov 30, 2018
Revenue	0.21	0.28	0.2	0.03	-	-
Revenue Growth (YoY)	-22.67%	45.38%	551.99%	-	-	-
Cost of Revenue	0.22	0.29	0.25	0.33	-	-
Gross Profit	-0.01	-0.01	-0.05	-0.3	-	-
Selling, General & Admin	2.65	3.31	6.26	10.97	4.48	5.78
Research & Development	0.06	0.13	1.07	1.88	3.54	3.24
Operating Expenses	2.71	3.44	7.34	12.85	8.02	9.02
Operating Income	-2.73	-3.45	-7.39	-13.15	-8.02	-9.02
Interest Expense	-1.25	-1.38	-0.51	-0.3	-1.46	-0.16
Other Non Operating Income (Expenses)	3.65	3.42	-0.3	-0.02	-0.21	-0.09
EBT Excluding Unusual Items	-0.32	-1.41	-8.2	-13.46	-9.69	-9.27
Other Unusual Items	-0.17	-0.64	-0.04	-0.03	-0.59	-
Pretax Income	-0.49	-2.05	-8.24	-13.49	-10.28	-9.27
Net Income	-0.49	-2.05	-8.24	-13.49	-10.28	-9.27
Preferred Dividends & Other Adjustments	1.42	1.44	0.5	0.86	-	-
Net Income to Common	-1.91	-3.49	-8.74	-14.35	-10.28	-9.27
Shares Outstanding (Basic)	65	45	27	22	15	14
Shares Outstanding (Diluted)	65	45	27	22	15	14
Shares Change (YoY)	130.36%	67.13%	20.84%	47.34%	9.50%	31.23%
EPS (Basic)	-0.03	-0.08	-0.33	-0.65	-0.68	-0.67
EPS (Diluted)	-0.03	-0.08	-0.33	-0.65	-0.68	-0.67
Gross Margin	-6.02%	-3.16%	-26.20%	-	-	-
Operating Margin	-1302.56%	-1211.74%	-3777.44%	-43818.05%	-	-
Profit Margin	-912.15%	-1228.79%	-4469.02%	-47834.05%	-	-
EBITDA	-2.68	-3.4	-7.34	-13.1	-7.97	-
D&A For EBITDA	0.05	0.05	0.05	0.05	0.05	-
EBIT	-2.73	-3.45	-7.39	-13.15	-8.02	-9.02

Updated Jun 16, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.